ACT supports the production and distribution of a microbial restoration product that is saving lives and driving breakthrough research.


Our mission is to save lives through microbial restoration. Through our partnership with the University of Minnesota Microbiota Therapeutics Program, we developed the first stool donor program and are the only academic program in the world that is manufacturing therapeutic microbiota in accordance with Good Manufacturing Practice protocols, a requirement for all pharmaceutical products. To date, we have produced over 13,000 capsules used to treat C. difficile patients and to target illnesses in clinical trials across the country.

Clostridium difficile is an antibiotic resistant infection that infects roughly 500,000 patients each year. ACT’s partnership with the University of Minnesota treats C. difficile patients locally and provides therapeutics to providers around the United States. Our therapeutics have treated over 1,000 patients with a 98% success curative rate against recurrent C. difficile infections.


Deb's Story

Debra has battled Crohn's disease for years and suffered from horrific cases of C. difficile. She researched and learned about FMT, and eventually used the treatment which helped tremendously. She has a beautiful story and is living life to the fullest today!
Read more

Heidi's Story: A Family Member's Perspective

Heidi's sister suffered from C. difficile and received an FMT. In this video, Heidi shares her unique perspective as sje helplessly watching her loved one suffer. So many of us can relate and this is a beautiful testimony that will give you strength!
Read more

An Autism Story

From birth, our son suffered from chronic constipation, acid reflux, and food sensitivities despite being exclusively breastfed for one year(and myself going through an elimination while nursing).
Read more
View All Stories

Sign up for our Newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form